BANK VONTOBEL/CALL/MODERNA/140/0.1/20.09.24 | Market Closed - Euronext Paris 12:30:00 2024-07-02 EDT | ||
| 0.51 EUR | 0.00% |
|
| Current month | -10.53% | ||
| 1 month | -71.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-02 | 0.51 | 0.00% |
| 24-07-01 | 0.51 | -10.53% |
| 24-06-28 | 0.57 | -12.31% |
| 24-06-27 | 0.65 | -31.58% |
| 24-06-26 | 0.95 | -25.78% |
Real-time Euronext Paris
Last update July 02, 2024 at 12:30 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| PQ41V | |
| ISIN | DE000VM7WHJ3 |
| Date issued | 2024-01-04 |
| Strike | 140 $ |
| Maturity | 2024-09-20 (80 Days) |
| Parity | 10 : 1 |
| Emission price | 1.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.7 € |
|---|---|
| Lowest since issue | 0.318 € |
| Spread | 0.02 € |
| Spread % | 3.85% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.1
USD
Average target price
145.9
USD
Spread / Average Target
+24.59%
- Stock Market
- Warrants
- PQ41V Warrant
